Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases

被引：20
|
作者：
Papamichael, Konstantinos [1 ]
Clarke, William T. [1 ]
Vande Casteele, Niels [2 ]
Germansky, Katharine A. [1 ]
Feuerstein, Joseph D. [1 ]
Melmed, Gil Y. [3 ]
Siegel, Corey A. [4 ]
Irving, Peter M. [5 ]
Cheifetz, Adam S. [1 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA
[2] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[3] Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Los Angeles, CA 90048 USA
[4] Dartmouth Hitchcock Med Ctr, Dept Gastroenterol & Hepatol, Lebanon, NH 03766 USA
[5] Guys & St Thomas NHS Fdn Trust, Dept Gastroenterol & Hepatol, London, England
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2021年 / 19卷 / 04期
关键词：
D O I：
10.1016/j.cgh.2020.03.002
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：839 / +
页数：5
相关论文
共 50 条
  • [11] Uptake of drug monitoring of infliximab and adalimumab in inflammatory bowel disease in Australia
    Janko, N.
    Little, R. D.
    Sparrow, M. P.
    Gibson, P. R.
    Ward, M. G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 136 - 137
  • [12] Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
    Al-Bawardy, Badr
    Jenkins, Sarah M.
    Snyder, Melissa R.
    Frinack, Jody L.
    Ladwig, Paula M.
    Loftus Jr, Edward V.
    Willrich, Maria Alice V.
    CLINICAL BIOCHEMISTRY, 2023, 119
  • [13] Effectiveness of therapeutic drug monitoring of infliximab and adalimumab in inflammatory bowel disease patients. Systematic review and meta-analysis
    Petryszyn, P.
    Dybalski, L.
    Gola, K.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S324 - S325
  • [14] Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
    Kamal, Mahmoud E.
    Werida, Rehab H.
    Radwan, Mahasen A.
    Askar, Safaa R.
    Omran, Gamal A.
    El-Mohamdy, Marwa A.
    Hagag, Radwa S.
    INFLAMMOPHARMACOLOGY, 2024, 32 (05) : 3259 - 3269
  • [15] Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease
    Mayte Gil-Candel
    Juan José Gascón-Cánovas
    Elena Urbieta-Sanz
    Lorena Rentero-Redondo
    María Onteniente-Candela
    Carles Iniesta-Navalón
    International Journal of Clinical Pharmacy, 2020, 42 : 500 - 507
  • [16] Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease
    Gil-Candel, Mayte
    Gascon-Canovas, Juan Jose
    Urbieta-Sanz, Elena
    Rentero-Redondo, Lorena
    Onteniente-Candela, Maria
    Iniesta-Navalon, Carles
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (02) : 500 - 507
  • [17] Predictors of loss of response to adalimumab therapy: the importance of therapeutic drug monitoring in inflammatory bowel diseases
    Kurti, Z.
    Vegh, Z.
    Rutka, M.
    Gonczi, L.
    Farkas, K.
    Gecse, K.
    Golovics, P. A.
    Szalay, B.
    Molnar, T.
    Lakatos, P.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S249 - S249
  • [18] Predictors of Loss of Response to Adalimumab Therapy; the Importance of Therapeutic Drug Monitoring in Inflammatory Bowel Diseases
    Kurti, Zsuzsanna
    Vegh, Zsuzsanna
    Golovics, Petra A.
    Gecse, Krisztina
    Gonczi, Lorant
    Rutka, Mariann
    Farkas, Klaudia
    Molnar, Tamas
    Lakatos, Peter L.
    GASTROENTEROLOGY, 2016, 150 (04) : S423 - S423
  • [19] Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases
    Villemonteix, Juliette
    Guerin-El Khourouj, Valerie
    Hugot, Jean-Pierre
    Giardini, Caroline
    Carcelain, Guislaine
    Martinez-Vinson, Christine
    BIOLOGICALS, 2021, 70 : 17 - 21
  • [20] MIN score predicts primary response to infliximab/adalimumab and vedolizumab therapy in patients with inflammatory bowel diseases
    Shi, Yuan
    He, Wei
    Zhong, Ming
    Yu, Minhao
    GENOMICS, 2021, 113 (04) : 1988 - 1998
12345